General Notes
This product (Catalog No. DPABH-20136) is a rabbit-derived polyclonal antibody raised against human FAM83H, targeting the amino acid region 1000–1179 of the protein. It has been affinity purified by Protein A. FAM83H was first discovered during extensive computational analysis of the human genomic sequence and reported to be essential in dental enamel formation. Mutation of FAM83H is the main etiological factor for human autosomal dominant hypocalcified amelogenesis imperfecta. Moreover, recently, research into FAM83H has focused on its roles in the development and progression of human cancers. However, there are controversial reports for the role of FAM83H in human cancers. Earlier reports, which used microarray analysis, showed higher FAM83H expression in ovarian cancers compared with normal ovarian tissue. In addition, higher expression of the FAM83H gene is presented in the cancers of lung, breast, colon, liver, ovary, pancreas, and stomach. The roles of FAM83H in the progression of human cancers involve changes in the proliferation and invasiveness of cancer cells. In colon cancer cells, overexpression of FAM83H is suggested to be involved in the progression of cancer cells by disorganizing keratin cytoskeleton structures. In addition, FAM83H increases proliferation of prostatic cancer cells, hepatocellular carcinoma cells, and clear cell renal cell carcinoma cells. In hepatocellular carcinoma cells, activation of the MYC-FAM83H pathway increases the proliferation and invasion activity of cancer cells. Moreover, higher expression of FAM83H is associated with an increased recurrence rate of prostatic cancer patients and shorter survival of uterine cancer, hepatocellular carcinoma, and clear cell renal cell carcinoma patients. These findings suggest that FAM83H has a vital role in tumorigenesis and progression of human malignant tumors, and might be involved in the progression of various types of human cancers. However, the expression of FAM83H is down-regulated in astrocytoma and oligodendroglioma of the brain, and higher expression of FAM83H is associated with favorable prognosis of glioma and head and neck cancer patients. Therefore, there is a possibility that the role of FAM83H might be different according to the type of cells and further study is needed.
DPABH-20136 is suitable for use in Western blot (WB) (1:5,000–1:50,000) application.
DPABH-20136 is supplied as a liquid formulation in PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.
COA
Publication 
Loading ......
